EICHORCondition: HER2-Positive Primary Breast Cancer · Residual Invasive Breast Cancer · Sponsor: Daiichi Sankyo
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The Oncology Institute of Hope & Innovation | Anaheim, California, United States | — |
| Kaiser Permanente | Anaheim, California, United States | — |
| Kaiser Permanente | Baldwin Park, California, United States | — |
| Kaiser Permanente | Bellflower, California, United States | — |
| Kaiser Permanente | Fontana, California, United States | — |
| Orange Coast Blood and Cancer Care | Fountain Valley, California, United States | — |
| Kaiser Permanente | Harbor City, California, United States | — |
| Kaiser Permanente | Irvine, California, United States | — |
| Long Beach Memorial TCI | Long Beach, California, United States | — |
| Kaiser Permanente | Los Angeles, California, United States | — |
| Kaiser Permanente | Ontario, California, United States | — |
| Kaiser Permanente | Panorama City, California, United States | — |
+ 470 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04622319